These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

798 related items for PubMed ID: 29446853

  • 1. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor.
    Xie C, Wan X, Quan H, Zheng M, Fu L, Li Y, Lou L.
    Cancer Sci; 2018 Apr; 109(4):1207-1219. PubMed ID: 29446853
    [Abstract] [Full Text] [Related]

  • 2. Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma.
    Wang G, Sun M, Jiang Y, Zhang T, Sun W, Wang H, Yin F, Wang Z, Sang W, Xu J, Mao M, Zuo D, Zhou Z, Wang C, Fu Z, Wang Z, Duan Z, Hua Y, Cai Z.
    Int J Cancer; 2019 Aug 15; 145(4):979-993. PubMed ID: 30719715
    [Abstract] [Full Text] [Related]

  • 3. Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1.
    Lin B, Song X, Yang D, Bai D, Yao Y, Lu N.
    Gene; 2018 May 15; 654():77-86. PubMed ID: 29454091
    [Abstract] [Full Text] [Related]

  • 4. Bevacizumab promotes active biological behaviors of human umbilical vein endothelial cells by activating TGFβ1 pathways via off-VEGF signaling.
    Zhang X, Zhang Y, Jia Y, Qin T, Zhang C, Li Y, Huang C, Liu Z, Wang J, Li K.
    Cancer Biol Med; 2020 May 15; 17(2):418-432. PubMed ID: 32587778
    [Abstract] [Full Text] [Related]

  • 5. Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models.
    Wu XY, Xu H, Wu ZF, Chen C, Liu JY, Wu GN, Yao XQ, Liu FK, Li G, Shen L.
    Oncotarget; 2015 Dec 29; 6(42):44563-78. PubMed ID: 26575424
    [Abstract] [Full Text] [Related]

  • 6. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B, Singh J, Gingrich D, Angeles T, Albom M, Yang S, Chang H, Robinson C, Hunter K, Dobrzanski P, Jones-Bolin S, Pritchard S, Aimone L, Klein-Szanto A, Herbert JM, Bono F, Schaeffer P, Casellas P, Bourie B, Pili R, Isaacs J, Ator M, Hudkins R, Vaught J, Mallamo J, Dionne C.
    Cancer Res; 2003 Sep 15; 63(18):5978-91. PubMed ID: 14522925
    [Abstract] [Full Text] [Related]

  • 7. YLT192, a novel, orally active bioavailable inhibitor of VEGFR2 signaling with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Xia Y, Song X, Li D, Ye T, Xu Y, Lin H, Meng N, Li G, Deng S, Zhang S, Liu L, Zhu Y, Zeng J, Lei Q, Pan Y, Wei Y, Zhao Y, Yu L.
    Sci Rep; 2014 Aug 12; 4():6031. PubMed ID: 25112436
    [Abstract] [Full Text] [Related]

  • 8. YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors.
    Amino N, Ideyama Y, Yamano M, Kuromitsu S, Tajinda K, Samizu K, Hisamichi H, Matsuhisa A, Shirasuna K, Kudoh M, Shibasaki M.
    Clin Cancer Res; 2006 Mar 01; 12(5):1630-8. PubMed ID: 16533791
    [Abstract] [Full Text] [Related]

  • 9. SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo.
    Cao ZX, Zheng RL, Lin HJ, Luo SD, Zhou Y, Xu YZ, Zeng XX, Wang Z, Zhou LN, Mao YQ, Yang L, Wei YQ, Yu LT, Yang SY, Zhao YL.
    Cell Physiol Biochem; 2011 Mar 01; 27(5):565-74. PubMed ID: 21691074
    [Abstract] [Full Text] [Related]

  • 10. Isogambogenic acid inhibits tumour angiogenesis by suppressing Rho GTPases and vascular endothelial growth factor receptor 2 signalling pathway.
    Fan Y, Peng A, He S, Shao X, Nie C, Chen L.
    J Chemother; 2013 Oct 01; 25(5):298-308. PubMed ID: 24070138
    [Abstract] [Full Text] [Related]

  • 11. DCLAK11, a multi-tyrosine kinase inhibitor, exhibits potent antitumor and antiangiogenic activity in vitro.
    Guo XB, Chen XJ, Tong LJ, Peng X, Huang M, Liu HC, Liu H, Ding J.
    Acta Pharmacol Sin; 2015 Oct 01; 36(10):1266-76. PubMed ID: 26027659
    [Abstract] [Full Text] [Related]

  • 12. Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma.
    Song F, Hu B, Cheng JW, Sun YF, Zhou KQ, Wang PX, Guo W, Zhou J, Fan J, Chen Z, Yang XR.
    Cell Death Dis; 2020 Jul 24; 11(7):573. PubMed ID: 32709873
    [Abstract] [Full Text] [Related]

  • 13. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
    Huang SW, Lien JC, Kuo SC, Huang TF.
    Carcinogenesis; 2012 May 24; 33(5):1022-30. PubMed ID: 22436611
    [Abstract] [Full Text] [Related]

  • 14. Antitumor activity of anlotinib in malignant melanoma: modulation of angiogenesis and vasculogenic mimicry.
    Yang Q, Li Q, Fan H.
    Arch Dermatol Res; 2024 Jul 03; 316(7):447. PubMed ID: 38958761
    [Abstract] [Full Text] [Related]

  • 15. KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties.
    Nakamura K, Taguchi E, Miura T, Yamamoto A, Takahashi K, Bichat F, Guilbaud N, Hasegawa K, Kubo K, Fujiwara Y, Suzuki R, Kubo K, Shibuya M, Isae T.
    Cancer Res; 2006 Sep 15; 66(18):9134-42. PubMed ID: 16982756
    [Abstract] [Full Text] [Related]

  • 16. PBA2 exhibits potent anti-tumor activity via suppression of VEGFR2 mediated-cell proliferation and angiogenesis.
    Fang X, Xie H, Luo M, Chen Z, Wang F, Li Q, Wang X, Ding J, Fu L.
    Biochem Pharmacol; 2018 Apr 15; 150():131-140. PubMed ID: 29408327
    [Abstract] [Full Text] [Related]

  • 17. ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer.
    McCarty MF, Wey J, Stoeltzing O, Liu W, Fan F, Bucana C, Mansfield PF, Ryan AJ, Ellis LM.
    Mol Cancer Ther; 2004 Sep 15; 3(9):1041-8. PubMed ID: 15367698
    [Abstract] [Full Text] [Related]

  • 18. A novel inhibitor of c-Met and VEGF receptor tyrosine kinases with a broad spectrum of in vivo antitumor activities.
    Awazu Y, Nakamura K, Mizutani A, Kakoi Y, Iwata H, Yamasaki S, Miyamoto N, Imamura S, Miki H, Hori A.
    Mol Cancer Ther; 2013 Jun 15; 12(6):913-24. PubMed ID: 23548264
    [Abstract] [Full Text] [Related]

  • 19. Reduction in endothelial tip cell filopodia corresponds to reduced intravitreous but not intraretinal vascularization in a model of ROP.
    Budd S, Byfield G, Martiniuk D, Geisen P, Hartnett ME.
    Exp Eye Res; 2009 Nov 15; 89(5):718-27. PubMed ID: 19576214
    [Abstract] [Full Text] [Related]

  • 20. α-santalol inhibits the angiogenesis and growth of human prostate tumor growth by targeting vascular endothelial growth factor receptor 2-mediated AKT/mTOR/P70S6K signaling pathway.
    Saraswati S, Kumar S, Alhaider AA.
    Mol Cancer; 2013 Nov 22; 12():147. PubMed ID: 24261856
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.